Sumitomo Mitsui Trust Group Inc. Sells 19,128 Shares of Bristol Myers Squibb Company $BMY

Sumitomo Mitsui Trust Group Inc. lowered its stake in Bristol Myers Squibb Company (NYSE:BMY) by 0.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 5,072,993 shares of the biopharmaceutical company’s stock after selling 19,128 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Bristol Myers Squibb were worth $316,555,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $27,000. Addison Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $32,000. William Mack & Associates Inc. acquired a new stake in shares of Bristol Myers Squibb during the third quarter worth $35,000. Groupe la Francaise raised its position in shares of Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 501 shares during the period. Finally, Kilter Group LLC acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 1.7%

NYSE BMY opened at $62.46 on Friday. Bristol Myers Squibb Company has a twelve month low of $45.20 and a twelve month high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a market cap of $127.59 billion, a price-to-earnings ratio of 13.85, a PEG ratio of 0.33 and a beta of 0.19. The firm’s 50 day moving average price is $62.80 and its two-hundred day moving average price is $59.94.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 62.78%. The company’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.63 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.40 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is presently 55.88%.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BMY shares. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Guggenheim reissued a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Cantor Fitzgerald cut their price objective on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, October 8th. Daiwa Securities Group upped their price objective on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Piper Sandler decreased their target price on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a report on Monday, October 26th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $65.46.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.